Asieris Pharmaceuticals, a global pharma company, announced on Tuesday that it has dosed its first patient in Europe in its multinational, multicentre, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira.
The product has been developed as a novel non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL), a pre-cancerous condition caused by a persistent HPV infection.
The study is a multinational, multicentre, randomised, double blind, prospective, placebo-controlled phase III clinical trial to assess the efficacy and safety of APL-1702, Cevira in HSIL. It is an integrated combination of drug and device. Presently, the trial is open for recruitment.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval